CPS-11 (N-(droxymetl)thalidomide) a Thalidomide analogue, is a potent anti-cancer agent. CPS-11 inhibits NF-κB, activates NFAT, and repress cytokine expression through elevated ROS. CPS-11 exhibits a wider activity spectrum and higher potency against MM (multiple myeloma) cell lines.
CPS-11 abrogates ability of bone marrow stromal cells (BMSCs) to induce proliferation of MM cells, confirming its ability to target tumor cells in the bone marrow microenvironment[1].CPS-11 (0-200 μM, 0 or 4 h) shows virtually no effect on activation of p38 and only slight, transient activation of ATF2 and HSP27[2].CPS-11 (0-100 μM, 24 or 48 h) was no toxic to H157 cells, WT MEFs or the p38α-/- MEFs at doses as high as 100 μM[2].CPS-11 (50 μM, 24 or 48 h) does not induce apoptosis in H157 cells[2].
References:
[1]. Aragon-Ching JB, et al. Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):167-74.
[2]. Warfel NA, et al. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3502-9.
[3]. Ge Y, et al. Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Blood. 2006 Dec 15;108(13):4126-35.